Even with Indo, im not sure it is going to be the saviour we originally hoped. Two key details in that announcement and the following clarification:
1. "Formal agreements" have not yet been entered into.
2. It is for "late stage" clinical trials.
I still think it is a good step, but I think it could be some time before we see any trials in Indonesia.
Ann: R327 Efficacy against WHO Priority Pathogen Acinetobacter B, page-19
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.005(1.64%) |
Mkt cap ! $89.39M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 33.0¢ | 30.0¢ | $70.29K | 223.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 19448 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 61249 | 6 |
View Market Depth
| Last trade - 15.19pm 17/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |